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Objective. To assess the impact of low-to-moderate risk prostate cancer on patients’ quality of life (QoL) at diagnosis and within
the first year of treatment. Subjects and Methods.M e n( 𝑛 = 672) aged 50–75 years with prostate cancer (Gleason score ≤7 ,P S A≤
20ng/mLandclinicalstagingT1c–T2b)wereenrolledinfiveEuropeancountries.Patientscompletedfivequestionnaires,including
EORTC Quality of Life Questionnaire—Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire—Cancer 30
(QLQ-C30). Questionnaires were completed at baseline, at 3 monthsand 12monthsafter startingtreatment. Theprimaryendpoint
wasthechangeinQLQ-PR25urinarysymptomssubscalescorefrombaselinetotheassessmentat3months.Results.M ean(SD)age
was65.0(5.7)yearsand400(66%)menhadGleasonscore≤6prostatecancer.Themostfrequentlyusedinitialtreatmentwasradical
prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (𝑃 < 0.001),
indicating that urinary symptoms worsened after treatment. The score was lower at 12 months than at 3 months, but it was still
significantly higher than at baseline (𝑃 < 0.001). Hormonal treatment-related symptoms, sexual functioning, and sexual activity
scores significantly worsened at 3 and 12 months (all 𝑃 < 0.001). For the QLQ-C30 questionnaire, global health status/QoL score
significantlydecreasedatmonth3butwasnotdifferentfrombaselinebymonth12.Scalesforphysical,role,andsocialfunctioning,
and fatigue, showed significant deterioration at 3 and 12 months. Conclusions. Low-to-moderate risk prostate cancer may have a
substantial effect on patients’ QoL within one year following treatment.
1. Introduction
I n2 0 0 8 ,t h ee s t i m a t e dn u m b e ro fn e wp r o s t a t ec a n c e rc a s e s
worldwide was almost 900,000; this burden is expected to
increase to 1.7 million by 2030 due to the growth and aging
of the global population [1]. Prostate cancer was the most
frequently diagnosed male cancer (excluding skin cancer) in
Europe in 2008 with an estimated 382,000 cases or 22% of all
male cancers diagnosed [2]. Furthermore, it is the third most
common cause of cancer death in men in Europe after lung
and colorectal cancer, with over 89,000 deaths attributed to
prostate cancer in 2008.
The burden associated with prostate cancer diagnosis
i sh i g ha n ds t e m sf r o mt h ed i a g n o s i s ,t h ed i s e a s ei t s e l f ,
and the varying impact of the available treatment options.
The majority (90%) of men with low-risk prostate cancers
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receiveradicalintervention,with50–60%undergoingradical
prostatectomy as their primary treatment [3, 4]. Side effects
such as sexual dysfunction, urinary incontinence, bowel
problems,anxiety ,weakness,fatigue,hotflushes,andpainare
frequently experienced, depending on the type of treatment
given[5–9].Existingdataalsoconfirmtheimpactofdifferent
prostate cancer treatments, or the disease in general, on
quality of life (QoL) and patients’ emotional well-being [6,
7]. However, there is little (if any) information available
on the burden of illness in men diagnosed with low-to-
moderate risk prostate cancer. A recent study assessed the
long-term (5-year follow-up) QoL impact of treatments for
low or intermediate risk prostate cancer in 704 patients [10].
Men were treated with radical prostatectomy, external beam
radiotherapy,orbrachytherapy,withbrachytherapyshownto
cause the least impact on QoL. The present pan-European
study assessed the shorter-term impact of low-to-moderate
risk prostate cancer on patients’ QoL and anxiety/depression
(i.e., at diagnosis and within the first year of treatment) and
estimated healthcare consumption within the first year of
diagnosis.
2. Subjects and Methods
This was a prospective, 1-year, observational, pan-European
(Germany, France, Spain, Italy, and Sweden) study of men
aged 50–75 years with prostate cancer of low-to-moderate
r i s ko fp r o g r e s s i o n( G l e a s o ns c o r e≤ 7, PSA ≤ 20ng/mL and
clinical staging T1c–T2b according to D’Amico criteria of
low-intermediate risk [11]). Allincludedpatientswereable to
read and write in order to complete the study questionnaires.
Exclusion criteria comprised the following: Gleason score
≥ 8, PSA > 20ng/mL, or clinical staging ≥ T2c; previous
treatment for prostate cancer or use of prostate cancer-
related medications; the presence of any other cancer (except
basal cell carcinoma) within the previous 5 years, or any
uncured cancer diagnosed more than 5 years ago (with
clinical evidence of relapse in the previous 5 years). All
included patients provided written, informed consent. The
study was approved by the relevant Ethics Committees and
conducted in accordance with ICH GCP, the Declaration of
Helsinki 2008 and any applicable local requirements.
P a t i e n t sw e r ea s k e dt oc o m p l e t et h r e ev a l i d a t e dQ o L
questionnaires: European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire-Prostate
Cancer 25 (EORTC QLQ-PR25); EORTC Quality of Life
Questionnaire—Cancer 30 (EORTC QLQ-C30); and Euro-
QoL-5D (EQ-5D) [12–14]. Anxiety and depression were also
assessed, using the Hospital Anxiety and Depression Scale
(HADS) questionnaire. In addition, the Work Productivity
Assessment Index (WPAI) questionnaire was used to assess
effect of diagnosis and treatment on work productivity
and activity. All questionnaires were completed at baseline
(within 2 months of diagnosis and before any prostate cancer
treatment),andat3monthsand12monthsafterstartingpros-
tate cancer treatment. Questionnaires were completed in the
clinic in a quiet room, away from any influence of healthcare
professionals. In extenuating circumstances, questionnaires
c o u l db ec o m p l e t e da th o m ea n dr e t u r n e dt ot h ec l i n i cb y
post. Missing values were not imputed.
The primary study endpoint was the change in QLQ-
PR25 urinary symptoms subscale score from baseline to
the assessment at 3 months after the start of prostate can-
cer treatment. Secondary endpoints were changes in other
QLQ-PR25 subscale scores from baseline to the 3-month
assessment; changes in all QLQ-PR25 subscale scores from
baselinetotheassessmentafter12months’treatment;changes
in QLQ-C30 scores from baseline to the 3- and 12-month
assessments; difference from normative data (based on the
UKgeneralpopulation)inbaselineEQ-5DandHADSscores;
changes in EQ-5D scores from baseline to the 3- and 12-
month assessments; changes in HADS scores from baseline
to the 3- and 12-month assessments; and cost assessment for
p r o s t a t ec a n c e rs u b j e c t sb a s e do nt y p eo ft r e a t m e n ta d m i n -
istered, resource utilisation (visits/treatment), and indirect
costs captured using the WPAI.
A total of 134 patients per country were needed in
order to have 90% power to detect a difference of 4.9
from baseline to 3 months in QLQ-PR25 urinary symptoms
subscale scores. The Full Analyses Set (FAS) consisted of all
p a t i e n t sw h oc o m p l e t e dt h eb a s e l i n ea n dt h e3 - m o n t hQ L Q -
PR25 questionnaire and was used for the primary outcome
a n a l y s i s .Th eB a s e l i n eA n a l y s e sS e t( B A S )c o n s i s t e do fa l l
patients who completed the baseline EQ-5D and HADS
questionnaire. The primary endpoint was assessed for the
FAS population (observed cases) using a repeated measures
analysis of variance with the following covariates: age, centre,
initial treatment received, Gleason score, T-stage, PSA test
result, education status, and whether the subject had a
progressive benign prostatic hyperplasia (BPH) diagnosis
(definedbyacuteurinaryretention[AUR]/BPHsurgery).For
the study endpoints, two-sided 95% confidence intervals for
theadjustedmeanchangesfrombaselineinthequestionnaire
scores were calculated along with 𝑃 values from a two-sided
significancetestthatthemeanchangefrombaselinewaszero.
Asignificancelevelof0.05wasusedfortheprimaryendpoint.
3. Results
3.1. Patients. A total of 672 patients were enrolled, of whom
603 completed the baseline EQ-5D and HADS question-
naires (BAS population; 86 patients (18 centres) in France,
132 (20 centres) in Germany, 131 each in Italy (9 centres)
and in Spain (11 centres), and 123 (9 centres) in Sweden)
and 404 completed the baseline and 3-month QLQ-PR25
questionnaires (FAS population); 326 patients completed the
12-month QLQ-PR25 questionnaire. Information on why
patientsdidnotcompletethequestionnairewasnotcollected.
F o rt h eB A Sp o p u l a t i o n ,t h em e d i a ns t u d yd u r a t i o nw a s
398 days (range: 1 to 787 days). Demographic and baseline
characteristics are summarised in Table 1.M e a n( S D )a g e
was 65.0 (5.7) years and 400 (66%) men had Gleason score
≤6 prostate cancer. Mean (SD) PSA level at baseline was
7.2 (3.4) ng/mL. Demographic characteristics were largely
similar in subjects who did and those who did not complete
the questionnaires.Prostate Cancer 3
Table 1: Baseline demographics and clinical characteristics (BAS
population).
Overall
𝑁 = 603
Demographic characteristics
Age (yrs), 𝑛 603
Mean ± SD 65.0 ± 5.73
Median (range) 66.0 (50–75)
Education, 𝑛 (%)
Less than high school 242 (40%)
High school 179 (30%)
Some college/university 69 (11%)
College/university graduate 46 (8%)
Post graduate (M.S., Ph.D.) 15 (2%)
Do not care to answer 52 (9%)
Family history of prostate cancer, 𝑛 (%) 104 (17%)
Father 60 (10%)
Brother 38 (6%)
Grandfather 13 (2%)
Uncle 13 (2%)
Son 0
Disease characteristics
Total Gleason score, 𝑛 (%) 603
≤6 400 (66%)
7 203 (34%)
PSA
a (ng/mL), 𝑛 603
Mean ± SD 7.207 ± 3.4348
Median (range) 6.35 (0.01–19.30)
≤10ng/mL, 𝑛 (%) 505 (84%)
11–20ng/mL, 𝑛 (%) 98 (16%)
Clinical staging, 𝑛 (%) 603
T1a 8 (1%)
T1b 5 (<1%)
T1c 355 (59%)
T2a 123 (20%)
T2b 112 (19%)
Clinical BPH
b diagnosis, 𝑛 (%) 603
Yes 225 (37%)
Progressive BPH diagnosis
c, 𝑛 (%) 225
Yes 34 (15%)
aPSA: prostate-specific antigen.
bBPH: benign prostatic hyperplasia.
cDefined by acute urinary retention (AUR) and BPH-related surgery.
The most frequently used initial treatment for prostate
cancer was radical prostatectomy (71% of patients).
Other treatments were external beam radiotherapy (9%),
brachytherapy (3%), combined hormonal therapy/radio-
therapy (2%), hormonal therapy alone (1%), and radical
prostatectomy followed by salvage radiotherapy (<1%). Ten
percent of patients were subjected to active surveillance/
watchful waiting, and 2% received other treatment. A total
of 176 patients were receiving concomitant medications
for genitourinary conditions, the most common of which
were alprostadil (7%), tadalafil (7%), bicalutamide (6%), and
tamsulosin (6%).
3.2. QLQ-PR25. QLQ-PR25 urinary symptoms subscale
score was significantly increased at 3 months (𝑃 < 0.001),
indicating that urinary symptoms worsened after treatment
(Table 2) .Th esc o r ew a sl o w e ra t12m o n th sth a na t3m o n th s ,
but it was still significantly higher than at baseline (𝑃<
0.001).Ofthecovariatesassessed,age(𝑃 < 0.0001)andcentre
(𝑃 = 0.0003)w e r es i g n i fi c a n ti nr e l a t i o nt ot h i ss u b s c a l e
score. Analysis of QLQ-PR25 urinary symptoms subscale
score was also performed according to initial treatment of
prostate cancer. Among the 71% of subjects who underwent
a radical prostatectomy, statistically significantly increases
in QLQ-PR25 urinary symptoms subscale scores were seen
after treatment (𝑃 < 0.001), similar to the results for the
overall population. For subjects who underwent external
radiotherapy, a statistically significant increase in QLQ-PR25
urinary symptoms subscale score was seen at month 3 (𝑃=
0.047)b u tn o ta tm o n t h1 2( 𝑃 = 0.103). In patients managed
with an active surveillance approach, symptoms worsened
but this was not statistically significant at either time point.
In country-specific analyses, urinary symptoms significantly
worsened in all five countries at 3 months, and in Germany
a n dF r a n c ea t1 2m o n t h s .
Other QLQ-PR25 subscale score endpoints are reported
in Table 3. Hormonal treatment-related symptoms, sexual
functioning,andsexualactivityscoressignificantlyworsened
at3and12months(all𝑃 < 0.001).Incontinenceaidproblems
s c o r ei n c r e a s e d ,b u tt h i sw a so n l ys i g n i fi c a n ta t3m o n t h s
(𝑃 = 0.003; 𝑃 = 0.075 at 12 months).Therewas nosignificant
change in bowel symptoms score at either time point.
3.3. QLQ-C30. For the QLQ-C30 questionnaire, global
health status/QoL score significantly decreased at month 3
but was not different from baseline by month 12. Scales for
physical, role and social functioning, and fatigue, showed
significant deterioration at 3 and 12 months. No significant
change was observed in cognitive functioning, while emo-
tional functioning significantly improved. Pain score was
significantly worse compared with baseline at month 3 but
not at month 12. Nausea and vomiting score was largely
unaffected (Table 4).
3.4. EQ-5D, HADS, and WPAI. There was no significant
change from baseline in EQ-5D scores at 3 and 12 months
following treatment for prostate cancer (data not shown).
Compared with age-matched normative data (UK general
population), the health status (EQ-5D) of the study popu-
lation was similar to the general population at baseline and
month 12, but significantly worse 3 months after starting
treatment.
Anxiety score (HADS anxiety subscale) was significantly
reduced (𝑃 < 0.001) from baseline (5.3) at both 3 (4.4)
and 12 (4.3) months following the start of treatment. The
largest improvement at both time points was in the group of4 Prostate Cancer
Table 2: Change from baseline in QLQ-PR25 urinary symptoms subscale score (FAS population, observed cases).
QLQ-PR25 urinary symptoms
a,b 𝑛 Adjusted mean ± SE
𝑁 = 404
Adjusted mean change
from baseline (95% CI)
𝑁 = 404
𝑃 value for change from
baseline
𝑁 = 404
Baseline 401 14.7 ± 3.01
Month 3 403 24.1 ± 3.05 9.36 (7.47, 11.25) <0.001
Month 12 326 19.2 ± 3.03 4.43 (2.70, 6.16) <0.001
aCovariates included terms for age, centre, initial treatment received, Gleason score, T-stage, PSA test result, education status, and progressive BPH diagnosis.
bScale range is 0 to 100. Higher scores indicate worse symptoms.
Table 3: Change from Baseline in other QLQ-PR25 Subscale Scores (FAS Population, Observed Cases).
QLQ-PR25 subset
a 𝑛 Adjusted mean ± SE
𝑁 = 404
Adjusted mean change
from baseline (95% CI)
𝑁 = 404
𝑃 value for change from
baseline
𝑁 = 404
Incontinence aid poblems
c
Baseline 49 −0.9 ± 11.18
Month 3 202 15.0 ± 10.65 15.81 (5.76, 25.85) 0.003
Month 12 124 8.8 ± 10.83 9.63 (−1.01, 20.27) 0.075
Bowel symptoms
c
Baseline 399 6.2 ± 1.53
Month 3 399 6.8 ± 1.53 0.60 (−0.24, 1.45) 0.159
Month 12 318 7.0 ± 1.54 0.84 (−0.14, 1.81) 0.093
Treatment-related symptoms
c
Baseline 371 7.6 ± 1.82
Month 3 376 13.0 ± 1.85 5.42 (4.40, 6.43) <0.001
Month 12 306 12.7 ± 1.85 5.11 (4.00, 6.21) <0.001
Sexual Functioning
b
Baseline 293 79.7 ± 4.62
Month 3 221 53.1 ± 4.67 −26.54 (−30.57, −22.50) <0.001
Month 12 194 52.0 ± 4.67 −27.67 (−31.43, −23.91) <0.001
Sexual activity
b
Baseline 397 33.2 ± 4.75
Month 3 401 23.0 ± 4.73 −10.29 (−12.99, −7.59) <0.001
Month 12 323 25.8 ± 4.77 −7.39 (−10.34, −4.44) <0.001
aCovariates included terms for age, centre, initial treatment received, Gleason Score, T-stage, PSA test result, education status and progressive BPH diagnosis.
bRange for each scale is 0 to 100. Higher scores indicate better functioning.
cRange for each scale is 0 to 100. Higher scores indicate worse symptoms/more problems.
patients (𝑛=1 2 ) whose initial management was with watch-
ful waiting. However, depression score (HADS depression
subscale) did not change significantly. Compared with age-
matched normative data (UK general population), anxiety
was significantly lower (𝑃 < 0.001)i nt h es t u d yp o p u l a t i o n
at baseline, 3, and 12 months, while depression was similar at
all three time points.
Approximately25%ofpatientswereemployedatthetime
of entering the study. Fewer patients remained in work after
they received a prostate cancer treatment (19% at month 3
a n d1 6 %a tm o n t h1 2 ) .O na v e r a g e ,3 2w o r k i n gh o u r si nt h e
previous week were reported at baseline; these hours slightly
d e c r e a s e df o l l o w i n gi n i t i a lt r e a t m e n t .Th ea v e r a g em i s s e d
w o r k i n gh o u r sd u et op r o s t a t ec a n c e ri nt h ep r e v i o u sw e e k
was6hoursatbaselineandmonth3,and2hoursatmonth12.
BasedontheoverallWPAIscores,diagnosisandtreatmentof
prostate cancer had no impact on working productivity and
on regular daily activities over the course of the study.
Medical costs including resource utilisation associated
with prostate cancer diagnosis and/or treatment were anal-
ysed. Of 603 subjects in the BAS population, 96% (𝑛=
578)h a dac o n s u l t a t i o n ( s )w i t hah e a l t h c a r ep r o f e s s i o n a lf o r
management of their prostate cancer. The primary reason for
the consultation was related to diagnosis and/or monitoring
of their prostate cancer. Ninety-seven percent of subjects
(𝑛 = 586) had at least one type of procedure related toProstate Cancer 5
Table 4: Change from baseline in QLQ-C30 scales (FAS population, observed cases).
QLQ-C30 subset
a 𝑛 Adjusted mean ± SE
𝑁 = 404
Adjusted mean change
from baseline (95% CI)
𝑁 = 404
𝑃 value for change
from baseline
𝑁 = 404
Global health status/QoL scale
b
Baseline 400 74.2 ± 3.81
Month 3 401 71.0 ± 3.81 −3.19 (−5.26, −1.12) 0.003
Month 12 323 74.2 ± 3.82 −0.02 (−2.25, 2.22) 0.987
Physical functioning scale
b
Baseline 397 90.3 ± 2.24
Month 3 394 86.5 ± 2.29 −3.81 (−5.03, −2.59) <0.001
Month 12 322 88.3 ± 2.29 −1.95 (−3.18, −0.72) 0.002
Role functioning scale
b
Baseline 400 88.2 ± 3.17
Month 3 400 79.4 ± 3.27 −8.81 (−11.05, −6.58) <0.001
Month 12 324 84.5 ± 3.24 −3.77 (−5.65, −1.88) <0.001
Emotional functioning scale
b
Baseline 396 80.1 ± 3.88
Month 3 401 83.3 ± 3.86 3.20 (1.26, 5.13) 0.001
Month 12 323 86.3 ± 3.84 6.26 (4.37, 8.14) <0.001
Cognitive functioning scale
b
Baseline 302 82.5 ± 4.88
Month 3 305 81.3 ± 4.90 −1.21 (−2.92, 0.49) 0.162
Month 12 245 81.0 ± 4.89 −1.51 (−3.15, 0.13) 0.071
Social functioning scale
b
Baseline 399 89.2 ± 3.40
Month 3 400 82.3 ± 3.45 −6.89 (−8.92, −4.85) <0.001
Month 12 323 85.4 ± 3.43 −3.83 (−5.74, −1.92) <0.001
Fatigue scale
c
Baseline 399 12.8 ± 3.47
Month 3 399 18.0 ± 3.50 5.22 (3.53, 6.90) <0.001
Month 12 322 15.5 ± 3.50 2.78 (1.26, 4.30) <0.001
Nausea and vomiting scale
c
Baseline 402 4.0 ± 1.31
Month 3 401 4.0 ± 1.29 0.06 (−0.79, 0.92) 0.882
Month 12 325 4.2 ± 1.29 0.20 (−0.67, 1.07) 0.652
Pain scale
c
Baseline 399 17.9 ± 3.32
Month 3 400 21.2 ± 3.36 3.36 (1.26, 5.47) 0.002
Month 12 326 17.5 ± 3.32 −0.38 (−2.06, 1.29) 0.652
aCovariates included terms for age, centre, initial treatment received, Gleason Score, T-stage, PSA test result, education status, and progressive BPH diagnosis.
Family history of breast cancer was also included for role functioning, emotional functioning, and pain sclae. Ethnicity was also included for cognitive
functioning.
bRange for each scale is 0 to 100. Higher scores indicate better functioning.
cRange for each scale is 0 to 100. Higher scores indicate worse symptoms.
their prostate cancer management. Procedures were related
to diagnosis and/or monitoring of prostate cancer in 89%
of patients, with PSA testing and biopsy being the most
frequently performed. Procedures were related to prostate
cancer treatment in 83% of subjects, with more than half of
these (𝑛 = 285) undergoing a radical prostatectomy.
4. Discussion
In this observational study, the majority of patients recruited
were due to receive treatment of curative intent such as
radical prostatectomy, external radiotherapy, brachyther-
apy, and hormone therapy, despite having tumours of6 Prostate Cancer
low-to-moderate risk. For example, almost three-quarters of
patients (71%) underwent radical prostatectomy as primary
treatment.Overall, treatmentof prostate cancer had negative
effects on all six domains of the prostate cancer-specific
QLQ-PR25 questionnaire. Urinary symptoms were generally
worse after 3 months and although they improved after 12
months, they remained significantly worse than at baseline.
Incontinence aid problems were also worse after 3 months
than after 12 months (only significant versus baseline at
month 3). Unlike urinary symptoms, sexual functioning did
not tend to improve after one year compared with 3 months,
suggesting that the impact of treatment on sexual function
may be longer-lasting and more profound compared with
the effect on urinary symptoms. On the other hand, sexual
activity score did show a slight improvement after 12 months
compared with 3 months, although it remained significantly
lower compared with baseline. Bowel symptoms scores wors-
ened, particularly among patients whose initial treatment
included radiotherapy (data not shown), although overall
the change from baseline was not statistically significant.
Worsening of urinary symptoms among patients managed
with active surveillance may suggest an age-related natural
decline, although age was taken into account in our analyses
as a covariate.
The primary endpoint for the study was the change in
QLQ-PR25 urinary symptoms subscale score from baseline
totheassessmentat3monthsafterthestartofprostatecancer
treatment. For some prostate cancer interventions (e.g.,
radiation therapy), the adverse effects are not immediately
evident;the3-monthtimepointwasthereforeselectedonthe
basisthatthiswouldenabletheadverse impactofmostinter-
ventionstobecomeapparent.Theurinarysymptomssubscale
score was chosen in order to have a primary endpoint that
was common across all prostate cancer interventions. The
number of evaluable patients was less than planned, which
had the potential to adversely affect power. However, despite
this, statistically significant differences were observed for
t h ep r i m a r ye n d p o i n t ,b o t ho v e r a l la n di ne a c hi n d i v i d u a l
country.
Using the more general cancer QoL QLQ-C30 ques-
tionnaire, physical, role, and social functioning significantly
worsened following treatment, as did fatigue and pain symp-
toms. In contrast, emotional functioning improved after
treatment. Changes in QLQ-PR25 and C30 questionnaires
were not strongly correlated with health status (as assessed
by EQ-5D scores), which did not significantly change from
baseline. One possible explanation for this lack of correlation
is that the EQ-5D assessment may not have been sensitive
enough to reflect the changes in health-related QoL that
occur following interventions for prostate cancer.
Patients’ anxiety and depression levels were relatively
u n a ff e c t e da tt h et i m eo fd i a g n o s i s ,a sm e a ns c o r e sw e r e
within the normal range of the HADS questionnaire. These
scores might have been expected to deteriorate over time, as
other studies have shown a high incidence of anxiety, depres-
sion, and distress [7, 15]. However, depression remained
largely unchanged while anxiety actually lessened after treat-
ment. This is consistent with the improvement in emotional
functioning as measured by the subscale of the QLQ-C30
questionnaire. It is possible that therapeutic intervention
might allay patient fears and so reduce anxiety. Education
of patients, psychological support from healthcare providers
and caregivers, and the use of anxiolytic medications might
also have been factors in reducing anxiety and improving
emotional functioning.
The majority of patients (75%) were not working at study
entry, thereby limiting the data on the impact of prostate
cancer on work productivity. However, for those subjects
who did work our data suggest that any impact on work
productivity may be transitory, and improves over time,
following prostate cancer treatment.
Our study primarily examined the burden of low-to-
moderate risk prostate cancer from the perspective of the
disease state. Nevertheless, our findings are generally in
line with those from other studies that have assessed the
reported impact of prostate cancer treatment on various
aspectsofphysicalfunctioning.Radicalprostatectomy,radio-
therapy, hormonal therapy, and watchful waiting have all
been shown to have a negative impact on sexual function,
urinary function, and bowel function of patients treated for
prostate cancer [6, 8, 9, 15–18]. Most recently, an analysis
of 1655 men from the Prostate Cancer Outcomes Study
comparedlong-termurinary,bowel,andsexualfunctionafter
radicalprostatectomyorexternal-beamradiationtherapyfor
localised prostate cancer [19]. This study showed that these
treatments resulted in declines in all functional domains
during 15 years of follow-up. The absence of any significant
effect on bowel symptoms in our study may be explained
b yt h ef a c tt h a to n l ya p p r o x i m a t e l y1 0 %o fp a t i e n t sr e c e i v e d
external radiotherapy, the treatment most associated with
bowel toxicity [20].
A potential limitation of our study is that the results rely
on patient recall after 3 months and after 12 months. Our
studymayalsohavebenefitedfromalongerfollow-upperiod
than 12 months. In addition, because of the observational
n a t u r eo ft h es t u d y ,t h e r em a yb ed i ff e r e n c e si nf a c t o r s
such as age, Gleason score, and tumour stage according to
initialtreatmentreceived;thismayrestrictcomparisonofthe
data according to initial treatment type, and also prevented
any further subgroup analyses according to initial treatment
received. Another possible limitation is the high proportion
of patients treated with radical prostatectomy, which may
limit the external validity of our findings. However, it is
important to note that interventions were not restricted
in the study protocol, with treatment decisions left to the
physician/patient based on individual patient circumstances.
In this respect, our study population reflects real-life clini-
cal practice. Further, the proportion of patients treated by
surgery in this study is consistent with other published
data that show radical prostatectomy is the most common
treatment in men with low-to-moderate risk prostate cancer
[4, 21].
In the present study, statistically significant differences
compared with baseline were demonstrated for several of the
QoL subscales assessed; however, this does not necessarily
translate to clinically important effects. There is currently no
definition available as to what would represent a clinically
meaningful change in QLQ-PR25 scores, although someProstate Cancer 7
information is available on the minimal clinically important
difference in QLQ-C30 scores [22]. These data suggest that
changes in the range of 5–10% (or 5–10 points in the present
study) may be considered clinically significant.
QoL considerations are important in helping guide
treatment decision-making in patients with prostate cancer,
especially those at low-to-moderate risk of progression. The
majorityofthesepatientshaveafavourableprognosisandare
not destined to die of their disease even in the absence of
treatment. However, overtreatment of indolent disease may
be a problem given that the various treatment options can
h a v eas i g n i fi c a n tn e g a t i v ei m p a c to nap a t i e n t ’ sh e a l t hs t a t u s
and QoL. This study showed that, across France, Germany,
Italy, Spain, and Sweden, low-to-moderate risk prostate
cancerisusuallytreatedwithradicaltherapies.Thistreatment
strategyhadanegativeimpactonvariousdimensionsofQoL
in these patients during the one-year observation period.
Prostate cancer treatment was associated with a decrease in
urinary and sexual functioning and increase in hormonal
treatment-related symptoms. With some exceptions, the
impact on treatment-related functioning scales and symp-
tomstendedtobehigheratmonth3andtohavesomedegree
of improvement at month 12. Treatment of prostate cancer
had minimal effects on depression and anxiety, and a limited
impact on productivity among active workers.
In conclusion, low-to-moderate risk prostate cancer may
haveasubstantialeffectontheQoLofaffectedpatientswithin
one year following treatment. Our study provides further
supportive information on the QoL impact of treatments for
low-to-moderateriskprostatecancerandwillhelpphysicians
to tailordiscussionswith patientsand guide decision making
for disease management, particularly with regard to the
primary treatment chosen.
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